Thomas E Shelton
Overview
Explore the profile of Thomas E Shelton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
943
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zacharakis N, Huq L, Seitter S, Kim S, Gartner J, Sindiri S, et al.
J Clin Oncol
. 2022 Feb;
40(16):1741-1754.
PMID: 35104158
Purpose: Metastatic breast cancer (mBrCa) is most often an incurable disease with only modest responses to available immunotherapies. This study investigates the immunogenicity of somatic mutations in breast cancer and...
2.
Seitter S, Sherry R, Yang J, Robbins P, Shindorf M, Copeland A, et al.
Clin Cancer Res
. 2021 Aug;
27(19):5289-5298.
PMID: 34413159
Purpose: Adoptive cell transfer (ACT) of autologous tumor-infiltrating lymphocytes (TIL) can mediate durable responses in patients with metastatic melanoma. This retrospective analysis provides long-term follow-up and describes the effect of...
3.
Lo W, Parkhurst M, Robbins P, Tran E, Lu Y, Jia L, et al.
Cancer Immunol Res
. 2019 Feb;
7(4):534-543.
PMID: 30709841
Adoptive cell therapy (ACT) with T cells targeting neoantigens can mediate durable responses in patients with metastatic cancer. Cell therapies targeting common shared antigens for epithelial cancers are not yet...
4.
Goff S, Dudley M, Citrin D, Somerville R, Wunderlich J, Danforth D, et al.
J Clin Oncol
. 2016 May;
34(20):2389-97.
PMID: 27217459
Purpose: Adoptive cell transfer, the infusion of large numbers of activated autologous lymphocytes, can mediate objective tumor regression in a majority of patients with metastatic melanoma (52 of 93; 56%)....
5.
Tran K, Zhou J, Durflinger K, Langhan M, Shelton T, Wunderlich J, et al.
J Immunother
. 2008 Sep;
31(8):742-51.
PMID: 18779745
Adoptive cell therapy (ACT) with tumor-reactive lymphocytes in patients with refractory melanoma can result in tumor regression and prolonged survival. Generating tumor-reactive lymphocyte cultures is technically difficult and resource intensive;...
6.
Heemskerk B, Liu K, Dudley M, Johnson L, Kaiser A, Downey S, et al.
Hum Gene Ther
. 2008 May;
19(5):496-510.
PMID: 18444786
Adoptive cell transfer of tumor-infiltrating lymphocytes (TILs) after lymphodepletion mediates regression in 50% of patients with metastatic melanoma. In vivo persistence and telomere length of the transferred cells correlate with...
7.
Dudley M, Wunderlich J, Shelton T, Even J, Rosenberg S
J Immunother
. 2003 Jul;
26(4):332-42.
PMID: 12843795
The generation of T lymphocytes with specific reactivity against tumor antigens is a prerequisite for effective adoptive transfer therapies. Melanoma-specific lymphocyte cultures can be established from tumor infiltrating lymphocytes (TILs)...